---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-008794"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:25:35.668561+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics: elraglusib Phase 2 meets primary endpoint; 1-year survival 43.6% vs 22.5% in mPDAC

## Summary
- 1-year survival rate 43.6% in elraglusib+GnP arm vs 22.5% in GnP alone (p=0.002); median OS 9.3 vs 7.2 months (HR=0.63, p=0.016).
- 37% reduction in risk of death; ORR 27.7% vs 20.5%; multiple patients with complete/partial responses and 100% target lesion reduction.
- Favorable safety profile; TEAEs and SAEs similar between arms; 2 patients with previously inoperable lesions successful resected.
- Trial fully enrolled (286 patients); topline data expected 1H 2025; planned FDA engagement for Phase 3 registration trial.

## SEC filing metadata
- accession: 0001683168-24-008794
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316824008794/0001683168-24-008794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316824008794/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-008794
- JSON: https://secwatch.observer/filing/0001683168-24-008794.json
- Plain text: https://secwatch.observer/filing/0001683168-24-008794.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.